drugset / Trial / NCT05234736
A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
NaSingle-groupOpen-labelTreatment
Summary
This Phase 2 study will be an open-label and single course study to assess the safety, tolerability, PK and metabolite profile of CBL-514.
Timeline
- Start
- 2022-02-11
- Primary completion
- 2022-06-09
- Completion
- 2022-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CBL-514 | Unknown | 800 mg | Subcutaneous |
Indications
No indication recorded.